Processa Pharmaceuticals Inc
processapharmaceuticals.comProcessa Pharmaceuticals Inc (NASDAQ: PCSA) is a clinical-stage pharmaceutical development company that acquires and develops drug candidates, primarily analogs and deuterated analogs of existing approved drugs, with the goal of obtaining FDA marketing approval. The company generates no product revenue as of the 10-K filed March 18, 2026, and operates entirely on capital raised through equity offerings, debt financings, and potential future licensing or collaboration arrangements. Processa has no FDA-approved, licensed, or commercialized products, and its pipeline candidates have not yet demonstrated efficacy in clinical trials. The company holds a license option agreement with Sun Pharmaceuticals, as disclosed in its SEC filings. Leadership includes CEO George Ng, President of Research and Development David Young, Pharm.D., Ph.D., and Chief Development and Regulatory Officer Sian Bigora, Pharm.D. Processa carries accumulated deficits and expects to incur continued net losses, financing operations through capital markets including an effective shelf registration statement on Form S-3 as of the filing date.
Products & Services
Drug candidates based on analogs and deuterated analogs of approved drugs. Specific pipeline candidates and indications are not detailed in the provided filing excerpts. The company holds a license agreement with Sun Pharmaceuticals. No products are FDA-approved or commercialized as of the 10-K filed March 18, 2026.
Revenue Model
No product revenue. Processa finances operations through public and private equity offerings, debt financings, and potential future licensing and collaboration arrangements. The company expects to incur additional losses and requires ongoing external capital raises, as stated in the 10-K filed March 18, 2026.
Customers & Markets
No commercial customers as of the 10-K filed March 18, 2026. End market would be third-party payors including government health programs such as Medicare via CMS, commercial insurance, and managed healthcare organizations, contingent on future regulatory approval and commercialization.
Geographic Exposure
Primary regulatory focus is the United States, with reference to FDA approval pathways. European regulatory framework via EMA is also referenced. No commercial operations in any geography as of the 10-K filed March 18, 2026.
Financial Snapshot
Loading...
